DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Galloway-Mowat syndrome — screening already-approved drugs against its 10-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGalloway-Mowat syndrome maps to a 10-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for galloway-mowat syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
TP53RK binding protein (TPRKB) — TPRKB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet -drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7SZC · 1.71 Å · ligand D(-)-TARTARIC ACID (TAR). Experimental structure, not a prediction.
What the evidence adds up to
Galloway-Mowat syndrome is a rare autosomal-recessive disorder classically defined by microcephaly and nephrotic syndrome. In 2016, homozygous truncating mutations in WDR73 were found in two of 31 unrelated families, and biallelic missense mutations were later identified in seven affected individuals from four families by exome sequencing. Three-dimensional modelling predicted conformational changes from the missense mutations, supporting their pathogenicity. An additional 13 families with microcephaly and renal disease were negative for WDR73 mutations. Among WDR73-positive patients, the phenotype included cerebellar atrophy, thin corpus callosum, brain stem hypoplasia, occasional coarse face, late-onset and mostly slow-progressive nephrotic syndrome, and frequent epilepsy. WDR73 mutations were limited to those with classical features.
A 2011 review noted that the underlying gene had not been identified at that time, and that many reported cases focused on renal pathology, emphasising a diversity of clinical and pathological features. The authors argued that when neuroradiology and neuropathology of published cases were scrutinised, a fairly consistent clinical and neuropathological phenotype emerged. A 2017 case report described a girl with developmental delay, stunted growth, and dysmorphic features in whom nephrotic syndrome became apparent only in adolescence, later than the typical presentation before two years of life. A 2021 review stated that Galloway-Mowat syndrome is caused by mutations in the WDR73 gene in a subset of cases.
No drug treatment is mentioned in any of these abstracts. No clinical trial of any pharmacological intervention is reported. What is missing is any evidence that a drug can alter the course of the neurological or renal disease, any trial design that tests a repurposed compound, and any patient stratification that might identify which of the genetically heterogeneous cases could respond.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part A · 2016 · 37 citations · open access
Extending the mutation spectrum for Galloway–Mowat syndrome to include homozygous missense mutations in the WDR73 gene
AbstractGalloway-Mowat syndrome is a rare autosomal-recessive disorder classically described as the combination of microcephaly and nephrotic syndrome. Recently, homozygous truncating mutations in WDR73 (WD repeat domain 73) were described in two of 31 unrelated families with Galloway-Mowat syndrome which was followed by a report of two sibs in an Egyptian consanguineous family. In this report, seven affecteds from four families showing biallelic missense mutations in WDR73 were identified by exome sequencing and confirmed to follow a recessive model of inheritance. Three-dimensional modeling predicted conformational alterations as a result of the mutation, supporting pathogenicity. An additional 13 families with microcephaly and renal phenotype were negative for WDR73 mutations. Missense mutations in the WDR73 gene are reported for the first time in Galloway-Mowat syndrome. A detailed phenotypic comparison of all reported WDR73-linked Galloway-Mowat syndrome patients with WDR73 negative patients showed that WDR73 mutations are limited to those with classical Galloway-Mowat syndrome features, in addition to cerebellar atrophy, thin corpus callosum, brain stem hypoplasia, occasional coarse face, late-onset and mostly slow progressive nephrotic syndrome, and frequent epilepsy.
Neuropathological Homology in True Galloway-Mowat Syndrome
AbstractGalloway-Mowat syndrome is a rare condition that is likely hereditary though the underlying offending gene has not been identified, and is characterized by microcephaly and severe nephrotic syndrome culminating in childhood death. Some of the reported cases have abnormalities in neuronal migration and intractable seizures, but many of the described cases focus on the renal pathology and emphasize a diversity of clinical and pathological features. The case described herein includes a thorough neuropathological description, and when the neuroradiology and neuropathology of the previously published cases is scrutinized, a fairly consistent clinical and neuropathological phenotype emerges.
Saudi Journal of Kidney Diseases and Transplantation · 2017 · 3 citations · open access
Galloway-mowat syndrome - unusual form of nephrotic syndrome in adolescent
AbstractGalloway-Mowat syndrome (GMS), also acknowledged as Microcephaly-Hiatal hernia nephrotic syndrome, is an uncommon genetic disorder inherited as an autosomal recessive trait usually seen before two years of life. It is an exceptional multisystem genetic disorder with a collection of skeletal, neurological, facial, gastrointestinal, growth, and renal abnormalities. This case report describes GMS in a girl, suffering from developmental delay, stunted growth, and various dysmorphic features, in whom nephrotic syndrome became apparent at adolescent age.
Archives in Biomedical Engineering & Biotechnology · 2021 · 0 citations · open access
The Role of Mutations on Gene WDR73 in Galloway-Mowat Syndrome
AbstractGalloway-Mowat syndrome is a very rare genetic disorder characterized by a variety of physical and developmental abnormalities, especially neurological abnormalities and progressive primary kidney disease. Physical characteristics may include microcephaly (a condition that indicates that the size of the head circumference is significantly smaller than expected for the child’s age and sex) and, in some cases, protrusion of part of the stomach through an abnormal opening in the diaphragm. Galloway-Mowat syndrome is caused by changes (mutations) in the WDR73 gene in a subset of cases.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
